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Background: Little is known about the specific reasons for antipsychotic discontinuation or continuation from
patients’ or clinicians’ perspectives. This study aimed to assess the construct validity of 2 new measures of the
Reasons for Antipsychotic Discontinuation/Continuation (RAD): RAD-I (a structured interview assessing the patient’s
perspective) and RAD-Q (a questionnaire assessing the clinician’s perspective).
Methods: Data were used from a 12-week antipsychotic trial of schizophrenia patients in which the RAD was
administered at study entry and at study completion (or discontinuation). Construct validity was assessed through
comparisons of RAD responses, clinicians’ responses to a standard patient disposition form identifying reasons for
patient’s study discontinuation, and several standard psychiatric measures. Percent agreement quantified the
correspondence between patient and clinician scores.
Results: Patients indicating lack of improvement/worsening of positive symptoms as a ‘somewhat’ to ‘primary’
reason for medication discontinuation had statistically significantly less improvement in Positive and Negative
Syndrome Scale positive score than patients not reporting these as a reason (concurrent validity). Similar results
were observed for the RAD negative symptom, functional, social support, and adherence items, whereas the mood
and cognitive items were not significantly associated with change scores on standard psychiatric measures.
Responses to the RAD were also weakly associated with variables that theoretically should not be related to them
(divergent validity). Level of agreement between the clinician- and patient-rated RAD scores was high (60%-100%).
Conclusions: Initial validation of the RAD suggests that the instruments are valid tools for gathering detailed
information regarding reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’
perspectives.
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Treatment discontinuation among patients with schizo-
phrenia is considered a proxy measure of a medication’s
effectiveness, reflecting its efficacy, safety, and tolerabil-
ity from both patients’ and clinicians’ perspectives [1,2].
Both clinical trial and observational research has shown
that adherence to antipsychotic treatment is low [1-4]. A
recent registry study by Tiihonen et al. [4] reported that
only 58.2% of patients in Finland collected a prescription
for an antipsychotic during the first 30 days after hos-
pital discharge and only 45.7% continued their initial
treatment for 30 days or longer. Although the reasons
for medication discontinuation are recognized as being
of great clinical importance, prior research has assessed
these reasons only at a broad or upper level, focusing on
broad categories including lack of medication efficacy,
medication intolerability, patient decision, and ‘other’.
Furthermore, no information on why patients continue
on antipsychotic treatment is typically captured in clin-
ical trials.
Interestingly, although the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) schizophre-
nia study demonstrated that patients discontinued anti-
psychotic treatment primarily due to ‘patient decision’
(followed by lack of efficacy and intolerability), the main
drivers of ‘patients’ decisions’ are unclear. It has been
previously noted [5] that because the drivers of ‘patient
decision’ are unclear, the true rate of discontinuation
due to medication intolerability has likely been underes-
timated. The idea that ‘patient decision’ might be a
proxy for medication intolerability seems incongruent
with several studies showing that patients’ perceptions of
medication’s benefits and early treatment response are
the primary predictors of treatment continuation and
discontinuation [6-10]. Importantly, identifying the spe-
cific reasons for continuing or discontinuing antipsycho-
tics will allow for a more granular understanding of the
specific elements that lead to discontinuation and help
clinicians better tailor following treatment to patients’
needs.
In order to address this gap, 2 new measures of the
Reasons for Antipsychotic Discontinuation/Continuation
(RAD) were developed: The RAD-I (a structured inter-
view assessing the patient’s perspective) and the RAD-Q
(a questionnaire assessing the clinician’s perspective)
[11,12]. The present study examined the construct valid-
ity of the 2 RAD measures using data from a 12-week
clinical trial of patients with schizophrenia.
Methods
RAD development
Two RAD scales were developed – the RAD-I was
designed as a structured interview assessing the patient’s
perspective, and the RAD-Q was developed as aquestionnaire assessing the clinician’s perspective (see
Appendix 1). The items for the preliminary versions of
the RAD were selected based on a comprehensive litera-
ture review, a patient interview pilot study, and input
from an expert working group. Patients with schizophre-
nia or schizoaffective disorder and their clinicians com-
pleted the draft measures and structured cognitive
debriefing interviews assessing the measures’ compre-
hensibility, clarity, and comprehensiveness. The draft
measures were further revised following cognitive
debriefing interviews with clinicians, patients, and inter-
viewers. A more comprehensive description of the quali-
tative work undertaken to develop these scales has
previously been presented [11,12]. The scales are avail-
able from the corresponding author upon request.
Both the RAD-Q and the RAD-I have 2 sections: one
to assess reasons for antipsychotic discontinuation
(administered only if treatment is being discontinued)
and the other to assess reasons for antipsychotic con-
tinuation (administered only if treatment is continuing).
Briefly, the RAD instruments contain statements related
to why a patient or clinician may choose to stop or con-
tinue an antipsychotic, such as ‘This medication did not
sufficiently improve positive symptoms (e.g., hallucina-
tions, delusions)’; ‘Non-life threatening side effects
(Please list up to 5)’; and ‘Financial cost of the medica-
tion’. The RAD-I and RAD-Q each include 25 items
assessing reasons for medication discontinuation and 21
(RAD-I) or 18 (RAD-Q) items assessing reasons for
medication continuation. The RAD-Q is completed by a
clinician who responds to whether each item was not a
reason, or was a minor, somewhat important, or primary
reason for discontinuation/continuation. The RAD-I is
completed by interviewing the patient using simple dir-
ect questions (e.g., ‘Why did you stop taking the anti-
psychotic?’). Vague or incomplete responses are queried
for specific reasons. The interviewer then maps the
patient’s responses onto statements similar to those in
the RAD-Q and asks the patient how important each
was in the decision to discontinue/continue. The RAD
version used in this clinical trial has since undergone
some relatively minor changes, particularly in the scor-
ing of the RAD-I. The RAD scales are available upon re-
quest from the third author.
Study design
To examine the validity of the RAD measures, we
used data from a randomized, double-blind study
(NCT00337662) exploring the relationship between
early response to an antipsychotic medication and sub-
sequent improvement in psychopathology. Patients aged
18 years or older with a diagnosis of schizophrenia,
schizoaffective disorder, or schizophreniform disorder,
according to the Diagnostic and Statistical Manual of
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in the study, provided they met a set of symptom se-
verity criteria at screening.
Patients were treated in an open-label fashion with ris-
peridone (2–6 mg/day) for 2 weeks, at which time early
response status was determined in a double-blind man-
ner. Patients who showed early response continued to
receive risperidone for the duration of the study.
Patients who did not show an early response to risperi-
done were randomized in a double-blind manner (1:1)
to either olanzapine (10–20 mg/day) or risperidone (2–
6 mg/day) for 10 weeks. Further details about the study
design and core findings are available elsewhere [13].
Written informed consent was obtained from each pa-
tient and the study was approved by the Ethics commit-
tee from each institution in which it was conducted and
the study was done in accordance to the Declaration of
Helsinki.
Study measures
A number of validated standard psychiatric measures
were used to assess the validity of the RAD. These mea-
sures included the Positive and Negative Syndrome Scale
(PANSS) [14,15], Quality of Life Scale (QLS) [16], Modi-
fied Schizophrenia Care and Assessment Program
Health Questionnaire (SCAP-HQ) [17], and the standard
patient disposition form used by clinicians in clinical
trials to identify the reason for study discontinuation.
The PANSS is one of the most well studied scales for
symptom severity in schizophrenia with demonstrated
internal consistency, reliability, and validity, multiple fac-
tor structure assessments [15,18] and anchoring to other
clinical measures [19]. The QLS was designed to assess
symptoms of functional deficit in schizophrenia patients,
and the initial validation included assessments of con-
struct validity, factor analysis, and inter-rater agreement
[16]. The SCAP-HQ was developed to assess outcomes
of routine care for patients with schizophrenia, with
items drawn from existing measures, and validated in a
sample of over 1500 patients assessing the factor struc-
ture, internal consistency, convergent validity, respon-
siveness to change, and test-retest reliability [17].
The RAD-Q and RAD-I were administered at baseline
(referring to the medication discontinued just prior to
entering the trial) and at Week 12 (referring to the study
drug). If a patient discontinued prior to Week 12, the
RAD scales were to be completed at study endpoint (re-
ferring to the study drug). While some psychiatric mea-
sures were administered at every study visit, at a
minimum, the above measures were administered at
baseline and Week 12 (or study discontinuation), corre-
sponding with RAD administration. Endpoint RAD data
was the focus of this current analysis as this was pro-
spectively assessed and allowed for comparison withchanges in symptom rating scales captured during the
trial.
The standard patient disposition form administered at
study endpoint captured the broad or upper-level reason
for discontinuation from the physician’s perspective.
Options included: adverse event, lack of efficacy, proto-
col violation, patient decision, physician decision, and
parent/caregiver decision. For patients who completed
the study (i.e., did not discontinue early), the study staff
would select ‘patient completed’ and no additional infor-
mation was captured.
Analysis methods
Summary statistics were utilized to describe the demo-
graphic and baseline patient characteristics for the study
population. To assess the impact of patients without
RAD data on the generalizability of our findings, the
characteristics of patients with and without RAD data
were compared using t- and chi-square tests.
Multiple assessments of concurrent validity utilizing
relationships of the RAD and the standard patient dis-
position measure and relationships between the RAD
and symptom severity scales were used to establish con-
struct validity. First, the percentage of times RAD rea-
sons for discontinuation were in agreement with
clinicians’ reported reasons for discontinuation using the
standard patient disposition form was computed. For in-
stance, patients who discontinued due to an adverse
event per standard disposition form were considered to
have a matching response on the RAD if the clinician
identified (on the RAD-Q) an adverse event as the ‘most
important’ reason for discontinuing. In addition, analysis
of variance was utilized to assess differences in RAD
component scores across these standard disposition
form groups.
The validity of each RAD item was assessed by cat-
egorizing patients into 2 groups based on their RAD re-
sponse: patients who responded that the reason was
‘somewhat important’, ‘very important’, or ‘primary’ rea-
son for discontinuation (or continuation) versus patients
who responded that the item was ‘not a reason’ for dis-
continuation (or continuation). These 2 groups were
then compared on their differentiation on corresponding
symptom scale scores. For example, to assess the RAD
item ‘positive symptoms not sufficiently improved’, group
differences in change from baseline to discontinuation in
PANSS positive symptom scores were assessed. To as-
sess divergent validity, it was hypothesized that effect
sizes between the above groups would be stronger for
the corresponding scale (e.g., RAD positive items with
the PANSS positive subscale) than other measures (e.g.,
RAD positive items with PANSS negative subscale,
PANSS mood subscale, PANSS functional subscale, qual-
ity of life, social support, pulse, and weight). Agreement
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RAD-I was compared using Pearson’s correlation coeffi-
cient, percentage agreement, and the kappa coefficient.
Results
Figure 1 summarizes the patient disposition and RAD
data collection during the study. RAD data were
obtained from 160 of the 236 patients who discontinued
and from 321 of the 360 patients who completed the
trial. Table 1 summarizes the baseline characteristics for
patients with baseline and with post-baseline RAD data.
Patients had a mean PANSS total score of about 93, and
a mean Clinical Global Impressions of severity score of
4.6, indicating being moderately to markedly ill. To as-
sess whether the population of patients with RAD data
was representative of the population entering the trial,
baseline and demographic data were compared between
patients with and without RAD post-baseline data. The
populations were similar, with no statistically significant
differences.
The RAD-Q item that was selected as the ‘single most
important’ reason for discontinuation more than any
other item was ‘insufficient improvement/worsening of
positive symptoms’ (24.3%) followed by medication ad-
verse events (22.4%). For approximately 18%, no single
reason was selected as the most important reason. The
most common reasons for continuing the medication
based on the RAD-Q were benefits for positive symp-
toms (46.7%) and patient perceptions of improvement
(e.g., patient believed he/she was now better) (15.4%).
For approximately 15% of the patients, no single most
important reason was given. Rates of specific reasons for
discontinuation and continuation from the patient inter-
view (RAD-I) were similar.
Based on the standard patient disposition form, ‘pa-
tient decision’ (33.9%, excluding patients who were lostFigure 1 Overview of patient disposition and RAD data collection. Ab
Continuation.to follow-up) was the most common reason for study
discontinuation. Figures 2 and 3 provide an assessment
of concurrent validity of the RAD utilizing patient
groups based on the standard patient disposition form.
Specifically, Figure 2 summarizes the RAD primary rea-
son for discontinuation by reasons stated in the standard
patient disposition form. Over three-fourths (82.6%) of
patients discontinuing medication due to ‘lack of effi-
cacy’ per the standard trial form had lack of efficacy as
the single most important reason for discontinuation on
the RAD-Q. Similarly, 92.3% of patients with a standard
form reason of ‘adverse event’ identified a RAD-Q toler-
ability item as the single most important reason. Rates
were slightly lower for the RAD-I, though there was still
strong concordance. Approximately 50% of those with
‘other’ reasons on the standard form identified adverse
events and lack of efficacy reasons on the RAD. ‘Patient
decision’ on the standard form reflected a mix of reasons
on the RAD: lack of efficacy (42%), intolerability (32%),
and other reasons (26%; e.g., non-adherence).
Figure 3 displays the correspondence between RAD
discontinuation component scores to the standard pa-
tient disposition form discontinuation reason groups.
For example, patients with an adverse event reason per
the standard form had statistically significantly higher
RAD-Q adverse event component scores than patients
with ‘lack of efficacy’ or patients with ‘other’ as their
standard form reason for discontinuation.
Table 2 summarizes the assessment of concurrent val-
idity for RAD discontinuation items. Patients for whom
lack of improvement of positive symptoms was ‘a some-
what important reason’, ‘a very important reason’, or ‘a
primary reason’ for medication discontinuation on the
RAD-Q and RAD-I had statistically significantly less im-
provement in PANSS positive score than patients for
whom this was not a listed reason. For the RAD-Q,breviations: RAD=Reasons for Antipsychotic Discontinuation/




All patients with post-
baseline RAD data
(N= 596) (N= 481)

















Living Situation,% 57.6 56.5
No/Limited Supervision
PANSS Total, mean (SD) 92.5 (13.8) 92.3 (13.3)
MADRS Total, mean (SD) 16.2 (9.2) 16.0 (9.3)
CGI-Severity, mean (SD) 4.6 (0.6) 4.6 (0.6)
No statistically significant (p < .05) differences were found between patients
with and without a post-baseline RAD measurement.
CGI = Clinical Global Impressions; MADRS =Montgomery-Asberg Depression
Rating Scale; N = number of patients; PANSS = Positive and Negative Syndrome
Scale; RAD= Reasons for Antipsychotic Discontinuation/Continuation;
SD= standard deviation.
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(relative to PANSS negative scores), mood (relative to
PANSS Anxiety/Depression), functioning (relative to
QLS total), social support (relative to QLS interper-
sonal relations), and adherence (relative to SCAP ad-
herence). For the RAD-I, similar results were observedFigure 2 Assessment of RAD responses (RAD-Q most important reason) s
Abbreviation: RAD-Q= Reasons for Antipsychotic Discontinuation/Continuafor cognition, functioning, and social support, though
no significant differences were found for mood.
Table 3 summarizes the assessment of concurrent val-
idity for RAD continuation items. Patients for whom
‘benefits for positive symptoms’ on the RAD-Q or RAD-
I were ‘a somewhat important reason’, ‘a very important
reason’, or ‘a primary reason’ for continuing the medica-
tion had statistically significantly greater improvement
in PANSS positive symptom scores relative to patients
who indicated positive symptoms were ‘not a reason’ for
continuing. Similar results were observed for the RAD
negative symptom question, mood, cognition, and func-
tioning, though no significant differences were observed
for social support.
To assess divergent validity, differences between the
analysis groups in Tables 2 and 3 were assessed using
scales hypothesized to have a lesser relationship with the
RAD item. Patients for whom the RAD-Q indicated
positive symptoms were a ‘somewhat’ to ‘primary’ reason
for discontinuation (compared to those indicating posi-
tive symptoms were not a reason) had a stronger rela-
tionship with PANSS positive symptoms (effect
size = 0.66) than with all other PANSS subscales, the
QLS, and with physiologic outcomes (i.e., weight, pulse;
absolute effect size range of 0.14 to 0.59). Similarly, for
the RAD-I assessment of positive symptoms, the group
effect size was 0.54 for the PANSS positive subscale and
ranged from 0.08 to 0.44 for other measures.
Agreement between the corresponding items on the
clinician (RAD-Q) and patient-interview (RAD-I) based
scores was high (range 60% to 100%) for all items (see
Table 4). Agreement was slightly higher for discontinu-
ation items relative to continuation items and higher for
items covering issues other than efficacy and safety, such
as cost, insurance, and social support. Correlations were
also high (r > .5) except for the ‘unable to connect with
members of the treatment team’ item. Chance-corrected
agreement (Kappa coefficients) ranged from 0.42 to 1.00tratified by standard form reason for discontinuation post-enrollment.





























Figure 3 Assessment of RAD responses (RAD-Q component scores) stratified by standard form reason for discontinuation post-enrollment.
Abbreviation: RAD-Q= Reasons for Antipsychotic Discontinuation/Continuation questionnaire assessing the clinician’s perspective.
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as defined by Landis and Koch [20].
Discussion
This study provided evidence supporting the construct
validity of the first instruments developed to assess the
specific reasons for antipsychotic discontinuation or con-
tinuation from patients’ and clinicians’ perspectives. This
validation study, using data from a 12-week clinical trial,
supports the RAD as a valid tool in psychiatric research
and suggests it may also be of utility in clinical practice.
Strong agreement was observed between the reasons clini-
cians identified on the RAD and the reasons they identified
on the standard patient disposition form. Significant differ-
ences in the RAD component scores were found between
patient groups based on the standard disposition form. In
addition, patient groups based on the RAD differentiated
as hypothesized on validated standard psychiatric mea-
sures. Furthermore, agreement between the clinician- and
patient-rated RAD scores was high, suggesting that
patients’ and clinicians’ perspectives on antipsychotic treat-
ment discontinuation and continuation are reasonably
similar. However, the design of the trial did not require in-
dependent scorers for the 2 scales and thus conclusions
regarding the agreement are somewhat limited.
The results of these analyses are similar to those of
Weiden et al. [21] who developed the Rating of Medica-
tion Influences (ROMI), a standardized measure for
assessing attitudinal and behavioral factors influencing
patient compliance with antipsychotic medications. Ana-
lyses to assess the psychometric properties of the ROMI
demonstrated that the ROMI is a reliable and valid in-
strument to assess the subjective reasons for medication
compliance and noncompliance.
Lack of efficacy (specifically relating to positive symp-
toms), rather than adverse events, was found to be the
main driver of treatment discontinuation in this study
from both the clinicians’ and patients’ perspectives.Current findings are in agreement with previous re-
search [6-10] which suggests that lack of efficacy is the
main driver of medication discontinuation in patients
with schizophrenia. Study results also provide, for the
first time, important information on the specific reasons
that underlie a large but ambiguous discontinuation cat-
egory: ‘patient decision.’ Such patients were identified on
the RAD as having discontinued due to a mix of reasons,
led by lack of efficacy (42%) and followed by medication
intolerability (32%).
Results also suggest that improvement of positive
symptoms is the most common single reason for con-
tinuing antipsychotic medication (from both clinician
and patient perspectives). Although little research is
available on the reasons for continuing medication, this
is in agreement with Liu-Seifert et al. [8,9] who found
that patients’ perceptions of a beneficial effect of anti-
psychotic treatment, assessed using the ROMI, may be a
significant factor in treatment persistence and satisfac-
tory treatment outcome.
Understanding the specific reasons for medication dis-
continuation is of vital importance in usual care, where
switching of treatment regimen is prevalent. While there
is research supporting the benefits of switching when
warranted [22-24], others have challenged this notion
[25]. The CATIE study has given rise to multiple efforts
to provide guidance on medication switching [26-29].
However, these and other research [5] suggest that prior
medication and the reason for medication switching are
important factors in determining the optimal next steps
in treatment for the individual patient. Thus, a tool such
as the RAD, which can provide greater specificity
regarding reasons for medication change (or lack of
change) could be valuable in both furthering research
and improving clinical decision-making.
The current study has several limitations. First, data
for this study were derived from a clinical trial, and thus
may not be generalizable to patients with schizophrenia





RAD domain Item Comparator N Mean change (SE) p-value N Mean change (SE) p-value
Positive Symptoms Not Sufficiently Improved PANSS Positive
Yes 56 −3.2 (0.8) 43 −3.5 (0.8)
No 103 −6.8 (0.5) .001 117 −6.3 (0.5) .003
Positive Symptoms Worsened PANSS Positive
Yes 13 −1.8 (2.2) 16 −2.1 (1.6)
No 149 −5.9 (0.4) .089 144 −6.1 (0.4) .004
Negative Symptoms Not Sufficiently Improved PANSS Negative
Yes 30 −0.8 (0.8) 23 −2.5 (1.0)
No 124 −3.4 (0.5) .012 132 −2.9 (0.4) .738
Negative Symptoms Worsened PANSS Negative
Yes 6 −0.8 (1.3) 8 2.5 (1.1)
No 155 −2.9 (0.4) .330 147 −2.9 (0.4) .003
Mood Symptoms Not Sufficiently Improved PANSS Anxiety/Depression
Yes 24 −0.7 (0.8) 18 −2.2 (1.1)
No 138 −2.6 (0.3) .031 130 −2.4 (0.4) .866
Mood Symptoms Worsened PANSS Anxiety/Depression
Yes 13 −0.4 (1.8) 13 −2.2 (1.1)
No 149 −2.5 (0.3) .273 146 −2.6 (0.3) .743
Cognition Not Sufficiently Improved PANSS Cognition
Yes 16 −2.7 (1.3) 22 −0.6 (1.0)
No 142 −3.2 (0.4) .712 136 −3.4 (0.4) .014
Cognition Worsened PANSS Cognition
Yes 7 −2.1 (1.5) 14 0.8 (1.5)
No 158 −3.1 (0.4) .607 145 −3.3 (0.4) .004
Functioning Not Sufficiently Improved QLS Total Score
Yes 21 −7.7 (4.8) 18 −7.6 (5.1)
No 135 4.6 (1.5) .005 136 3.8 (1.5) .015
Functioning Worsened QLS Total Score
Yes 9 −15.2 (7.4) 12 −14.6 (6.2)
No 152 3.7 (1.4) .003 145 3.6 (1.4) .001
Social Support Friend/Family Did
Not Support
QLS Interpersonal Relations
Yes 6 −9.0 (3.5) 10 −4.3 (2.9)
No 154 1.8 (0.7) .003 158 2.3 (0.7) .021
General Symptoms Subject Believed
Symptoms Worse
PANSS Total Score
Yes 21 0.6 (4.4)
No 142 −17.3 (1.4) .001
Adherence Subject Not Adhering
to Medication
SCAP Adherence Item
Yes 11 2.0 (0.3)
No 133 1.4 (0.1) .023
Yes = “Somewhat” to “Primary Reason” was chosen; No= “Not a Reason” was chosen; N= number of patients; PANSS = Positive and Negative Syndrome Scale;
QLS =Heinrich Carpenter Quality of Life Scale; RAD = Reasons for Antipsychotic Discontinuation/Continuation; SCAP= Schizophrenia Care and Assessment Program;
SE = standard error.
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Table 3 Change in symptom domains per standard validated measures by RAD reasons for study drug continuation
Groups based on RAD-Q Groups based on RAD-I
RAD domain Item Comparator N Mean change
(SE)
p-value N Mean change
(SE)
p-value
Positive Symptoms Benefits PANSS Positive
Yes 215 −10.4 (0.4) 206 −10.7 (0.4)
No 20 −5.2 (1.5) .001 30 −5.6 (0.8) .001
Negative Symptoms Benefits PANSS Negative
Yes 111 −7.8 (0.5) 110 −7.6 (0.5)
No 90 −2.9 (0.5) .001 112 −3.5 (0.5) .001
Mood Items Benefits PANSS Anxiety/Depression
Yes 113 −5.7 (0.4) 139 −5.5 (0.3)
No 97 −3.4 (0.4) .001 83 −3.3 (0.4) .001
Cognition Items Benefits PANSS Cognition
Yes 108 −7.7 (0.5) 131 −7.1 (0.5)
No 102 −4.0 (0.4) .001 91 −4.1 (0.4) .001
Functioning Items Benefits QLS Total
Yes 137 25.1 (2.0) 141 23.4 (2.0)
No 81 7.3 (2.0) .001 88 8.5 (2.0) .001
Social Support Items Family/Friends Support QLS Interpersonal Relations
Yes 43 7.0 (1.4) 45 7.6 (1.3)
No 181 8.1 (0.8) .512 186 7.7 (0.8) .975
Yes = “Somewhat” to “Primary Reason” was chosen; No= “Not a Reason” was chosen; N= number of patients; PANSS = Positive and Negative Syndrome Scale;
QLS =Heinrich Carpenter Quality of Life Scale; RAD = Reasons for Antipsychotic Discontinuation/Continuation; SE = standard error.
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study, assessing the validity of the RAD in usual care set-
tings, is in progress. Second, this trial enrolled acutely
exacerbated psychotic patients with schizophrenia whoTable 4 Agreement between corresponding items on the RAD
Discontinuation items









Adverse Event 79.8 0.94
Finances 97.7 0.91
Insurance 99.4 0.91
Health System 98.3 0.91
Transportation 100.0 1.00
Social Support 96.7 0.82
Believed Better 95.5 0.80
Unable to Connect 98.3 0.30
Influence Another 93.7 0.62
Try New Medication 97.7 0.64had a mean PANSS score of about 93 at baseline. As a
result, patients and clinicians may have placed a pre-
mium on the amelioration of psychotic symptoms and








0.61 67.7 0.71 0.53
0.54 60.2 0.68 0.46
0.52 60.3 0.68 0.47
0.54 60.6 0.74 0.47
0.55 67.2 0.82 0.56
0.72 63.4 0.67 0.49
0.82 87.9 0.67 0.59
0.91 88.8 0.75 0.62
0.62 80.7 0.63 0.51
1.00 85.0 0.67 0.52
0.66 79.0 0.71 0.52
0.45 61.9 0.65 0.49
0.57 70.7 0.77 0.55
0.62 87.0 0.57 0.50
0.49 70.7 0.74 0.55
Table 5 Reasons for Antipsychotic Discontinuation/Continuation questionnaire assessing the clinician’s perspective
(RAD-Q)
Item Scoring Item Scoring
RAD-Q Discontinuation RAD-Q Continuation
1. This medication did not sufficiently improve positive
symptoms (e.g., hallucinations, delusions).
A 30. The medication has no serious safety issues that are
dangerous and potentially life-threatening for this patient
(e.g., seizures, heart arrhythmia, agranulocytosis).
A
2. This medication made positive symptoms worse. A 31. Benefits for positive symptoms (e.g., hallucinations, delusions). A
3. This medication did not sufficiently improve negative
symptoms (e.g., flat affect, lack of motivation).
A 32. Benefits for negative symptoms (e.g., flat affect,
lack of motivation).
A
4. This medication made negative symptoms worse. A 33. Benefits for the patient’s mood (e.g., depression). A
5. This medication did not sufficiently improve the patient’s
mood (e.g., depression).
A 34. Benefits for cognition (e.g., planning, attention,
memory).
A
6. The medication made the patient’s mood worse. A 35. Benefits for functional status (e.g., self-care activities
of daily living, or work).
A
7. This medication did not sufficiently improve cognition
(e.g., planning, attention, memory).
A 36. Financial cost of medication. A
8. This medication made cognition worse. A 37. The patient’s insurance adequately covers this medication. A
9. This medication did not sufficiently improve functional status
(e.g., the patient’s ability to work or live independently).
A 38. The patient is willing/able to negotiate the health-care
system to obtain this drug (e.g., getting prescriptions filled,
scheduling/attending appointments).
A
10. This medication made functional status worse. A 39. There are no problems with transportation (e.g., getting
to the pharmacy to refill medication).
A
11. A medication-related serious safety issue that was dangerous
and potentially life-threatening (e.g., seizures, heart arrhythmia,
agranulocytosis).
A 40. Social support (e.g., friends or family support the patient
in taking this medication).
A
12-16. Please list up to 5 non-life threatening side effects
experienced by the patient that were reasons for discontinuing
this medication.
A 41. Patient perceptions of improvement (e.g., the patient
believed he/she was now “better” and wants to continue
taking the medication).
A
17. Financial cost of the medication. A 42. The patient has formed a therapeutic alliance or
connection with members of the treatment team.
A
18. The patient’s insurance did not adequately cover
this medication.
A 43. Another person told this patient to continue taking the
medication (if so, what is the relationship of this person
to the patient?).
A
19. Difficulty negotiating the health-care system (e.g., getting
prescriptions filled, scheduling/attending appointments).
A 44. The patient has already tried other antipsychotics that
have not been as effective and/or tolerable.
A
20. Problems with transportation (e.g., getting to the pharmacy
to refill medication).
A 45-46. Other: Specify.
21. Social support (e.g., friends or family did not support
patient in taking this medication).
A 47-51. Please list up to 5 side effects the patient experiences
from this antipsychotic.
A
22. Patient believes he/she no longer needed the medication
because he/she was now “better.”
A Of all the reasons listed in items 30–51, is there one that
you consider to be the most important reason for
continuing this medication?
B
23. The patient believed the medication was
causing symptoms to become worse.
A
24. The patient was unable to connect with
members of the treatment team.
A
25. Another person told this patient to stop the
medication (if so, what is the relationship of the
person to the patient?).
A
26. The patient wished to try an antipsychotic
new to the market.
A
27. Potential interactions with another drug prescribed
for this patient?
A
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Table 5 Reasons for Antipsychotic Discontinuation/Continuation questionnaire assessing the clinician’s perspective
(RAD-Q) (Continued)
28. The patient was not adhering to the medication regimen. A
29. The patient developed a new medical condition
and this antipsychotic may have exacerbated the condition.
A
Of all the reasons listed in items 1–29, is there one that you
consider to be the most important reason for discontinuing
this medication?
B
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verely ill demonstrated that continuation and discontinu-
ation appear driven by the medication’s efficacy for
improving positive symptoms [30]. Third, the RAD has
not been evaluated outside the United States and until
additional research is conducted, its validity in other geo-
graphic regions is uncertain. Fourth, this trial utilized
preliminary versions of the RAD. While ongoing devel-
opment of the RAD resulted in only limited revisions,
confirmation of these results is needed. Fourth, a rela-
tively small number of patients discontinued from the
clinical trial and some of these did not provide RAD data,
which limited the analysis on reasons for medication dis-
continuation. Finally, the RAD is the first measure
designed to assess specific reasons for medication dis-
continuation or continuation from both patients’ and
clinicians’ perspectives and, thus, our lack of ability to
compare the instruments with an established and vali-
dated ‘gold standard’. The RAD is applicable for asses-
sing discontinuation/continuation of antipsychotics for
the treatment of schizophrenia and was not designed
for other disease states and medications. However, the
model used to develop and validate the RAD, begin-
ning with patient interviews and expert working
groups, could be of significant value in other areas
where medication adherence is critical.
Conclusions
This research provided support for the construct validity
of the RAD in a clinical trial population. Additional re-
search is needed to clarify whether the RAD, when not
used in the study of schizophrenia patients with acute
exacerbations, would provide similar results. Despite
current limitations, it appears these are valid instruments
to assess an important driver of treatment outcomes,
namely the patients and their physicians’ wish to con-
tinue or discontinue a given antipsychotic treatment
regimen.Appendix 1
The Reasons for Antipsychotic Discontinuation/
Continuation (RAD) scales were developed to assess the
specific reasons for antipsychotic discontinuation or
continuation. The RAD-I is a structured interviewassessing the patient's perspective and the RAD-Q a
questionnaire assessing the clinician's perspective.
Table 5 provides the specific questions and response
options for both the discontinuation and continuation
portions of the RAD-Q.
Item Scoring
A: Yes/No; If Yes, then choose one of the 4 options:
1) A minor reason; 2) a somewhat important reason;
3) a very important reason; 4) a primary reason
B: Yes/No; If Yes, then ‘Which item?’
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